Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension.

Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol (2009) 3.69

Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation (2010) 2.85

Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest (2008) 2.49

Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension. Am J Physiol Heart Circ Physiol (2010) 2.03

Pathogenic mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol (2007) 1.85

Validation of high-resolution echocardiography and magnetic resonance imaging vs. high-fidelity catheterization in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol (2010) 1.54

Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats. J Hypertens (2009) 1.11

A comparison of echocardiography to invasive measurement in the evaluation of pulmonary arterial hypertension in a rat model. Int J Cardiovasc Imaging (2010) 1.11

Bone morphogenetic protein signalling in heritable versus idiopathic pulmonary hypertension. Eur Respir J (2009) 1.11

PGC1α-mediated mitofusin-2 deficiency in female rats and humans with pulmonary arterial hypertension. Am J Respir Crit Care Med (2013) 1.06

Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension. Pulm Circ (2013) 0.90

Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology. J Am Heart Assoc (2013) 0.88

New perspectives for the treatment of pulmonary hypertension. Br J Pharmacol (2011) 0.87

Genetics of pulmonary arterial hypertension: do the molecular findings have translational value? F1000 Biol Rep (2010) 0.83

Pulmonary arterial hypertension: advances in pathophysiology and management. Indian J Pharmacol (2012) 0.79

BMP type II receptor as a therapeutic target in pulmonary arterial hypertension. Cell Mol Life Sci (2017) 0.76

Elevated microRNA-135a is associated with pulmonary arterial hypertension in experimental mouse model. Oncotarget (2017) 0.75

Constitutively active form of natriuretic peptide receptor 2 ameliorates experimental pulmonary arterial hypertension. Mol Ther Methods Clin Dev (2016) 0.75

The promise of recombinant BMP ligands and other approaches targeting BMPR-II in the treatment of pulmonary arterial hypertension. Glob Cardiol Sci Pract (2015) 0.75

Mesenchymal stromal cell therapy reduces lung inflammation and vascular remodeling and improves hemodynamics in experimental pulmonary arterial hypertension. Stem Cell Res Ther (2017) 0.75

A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell (2007) 9.20

ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol (2009) 7.94

Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol (2004) 5.79

ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation (2009) 5.49

Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation (2011) 5.16

Acute oxygen-sensing mechanisms. N Engl J Med (2005) 4.80

Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol (2009) 3.75

Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol (2009) 3.69

Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation (2007) 3.33

Mitochondrial dynamics--mitochondrial fission and fusion in human diseases. N Engl J Med (2013) 3.33

An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation (2006) 3.21

Vascular endothelial growth factor gene therapy increases survival, promotes lung angiogenesis, and prevents alveolar damage in hyperoxia-induced lung injury: evidence that angiogenesis participates in alveolarization. Circulation (2005) 3.00

Counterpoint: release of an endothelium-derived vasoconstrictor and RhoA/Rho kinase-mediated calcium sensitization of smooth muscle cell contraction are not the main effectors for full and sustained HPV. J Appl Physiol (1985) (2007) 2.98

Endothelin axis is upregulated in human and rat right ventricular hypertrophy. Circ Res (2012) 2.83

Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective, placebo-controlled, double-blind crossover trial. Arch Intern Med (2004) 2.78

Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med (2009) 2.64

Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. Am J Respir Crit Care Med (2009) 2.60

Counterpoint: Hypoxic pulmonary vasoconstriction is not mediated by increased production of reactive oxygen species. J Appl Physiol (1985) (2006) 2.48

Hypoxic pulmonary vasoconstriction. J Appl Physiol (1985) (2005) 2.38

Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest (2005) 2.32

Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation (2003) 2.22

Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications. Circulation (2009) 2.17

Diversity in mitochondrial function explains differences in vascular oxygen sensing. Circ Res (2002) 2.06

Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res (2004) 2.06

Fatty acid oxidation and malonyl-CoA decarboxylase in the vascular remodeling of pulmonary hypertension. Sci Transl Med (2010) 2.04

The role of Nogo and the mitochondria-endoplasmic reticulum unit in pulmonary hypertension. Sci Transl Med (2011) 1.95

The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle. J Mol Med (Berl) (2009) 1.94

The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci U S A (2007) 1.93

Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation (2002) 1.82

Dynamin-related protein 1-mediated mitochondrial mitotic fission permits hyperproliferation of vascular smooth muscle cells and offers a novel therapeutic target in pulmonary hypertension. Circ Res (2012) 1.81

Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. FASEB J (2012) 1.80

An evidence-based approach to the management of pulmonary arterial hypertension. Curr Opin Cardiol (2006) 1.76

Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation (2002) 1.75

An enzyme with a deep trefoil knot for the active-site architecture. Acta Crystallogr D Biol Crystallogr (2002) 1.72

GRK2-mediated inhibition of adrenergic and dopaminergic signaling in right ventricular hypertrophy: therapeutic implications in pulmonary hypertension. Circulation (2012) 1.71

Role of dynamin-related protein 1 (Drp1)-mediated mitochondrial fission in oxygen sensing and constriction of the ductus arteriosus. Circ Res (2013) 1.67

Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNFα contributes to the pathogenesis of pulmonary arterial hypertension. J Mol Med (Berl) (2011) 1.56

Validation of high-resolution echocardiography and magnetic resonance imaging vs. high-fidelity catheterization in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol (2010) 1.54

In vivo gene transfer of the O2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats. Circulation (2003) 1.54

Oxygen activates the Rho/Rho-kinase pathway and induces RhoB and ROCK-1 expression in human and rabbit ductus arteriosus by increasing mitochondria-derived reactive oxygen species: a newly recognized mechanism for sustaining ductal constriction. Circulation (2007) 1.48

Targeting cell motility in pulmonary arterial hypertension. Eur Respir J (2013) 1.47

Preferential expression and function of voltage-gated, O2-sensitive K+ channels in resistance pulmonary arteries explains regional heterogeneity in hypoxic pulmonary vasoconstriction: ionic diversity in smooth muscle cells. Circ Res (2004) 1.46

Endothelium-derived hyperpolarizing factor in human internal mammary artery is 11,12-epoxyeicosatrienoic acid and causes relaxation by activating smooth muscle BK(Ca) channels. Circulation (2003) 1.46

Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle's cycle. J Mol Med (Berl) (2011) 1.43

Lung ¹⁸F-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring of pulmonary arterial hypertension. Am J Respir Crit Care Med (2012) 1.42

Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology. Front Oncol (2013) 1.42

Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury. Am J Respir Crit Care Med (2005) 1.42

Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. Circulation (2015) 1.30

Dynamin-related protein 1 (Drp1)-mediated diastolic dysfunction in myocardial ischemia-reperfusion injury: therapeutic benefits of Drp1 inhibition to reduce mitochondrial fission. FASEB J (2013) 1.28

The role of k+ channels in determining pulmonary vascular tone, oxygen sensing, cell proliferation, and apoptosis: implications in hypoxic pulmonary vasoconstriction and pulmonary arterial hypertension. Microcirculation (2006) 1.26

Mitochondrial metabolic adaptation in right ventricular hypertrophy and failure. J Mol Med (Berl) (2010) 1.25

Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension. Chest (2010) 1.22

Absence of malonyl coenzyme A decarboxylase in mice increases cardiac glucose oxidation and protects the heart from ischemic injury. Circulation (2006) 1.21

Dehydroepiandrosterone reverses systemic vascular remodeling through the inhibition of the Akt/GSK3-{beta}/NFAT axis. Circulation (2009) 1.19

A metabolic remodeling in right ventricular hypertrophy is associated with decreased angiogenesis and a transition from a compensated to a decompensated state in pulmonary hypertension. J Mol Med (Berl) (2013) 1.18

O2 sensing in the human ductus arteriosus: regulation of voltage-gated K+ channels in smooth muscle cells by a mitochondrial redox sensor. Circ Res (2002) 1.17

Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study. Am J Physiol Lung Cell Mol Physiol (2007) 1.17

SIRT3 deacetylates and activates OPA1 to regulate mitochondrial dynamics during stress. Mol Cell Biol (2013) 1.15

The role of mitochondria in pulmonary vascular remodeling. J Mol Med (Berl) (2010) 1.15

CD36 expression contributes to age-induced cardiomyopathy in mice. Circulation (2007) 1.15

A dynamic and chamber-specific mitochondrial remodeling in right ventricular hypertrophy can be therapeutically targeted. J Thorac Cardiovasc Surg (2008) 1.15

Late gadolinium enhancement cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension. J Cardiovasc Magn Reson (2012) 1.14

Evaluation of a pharmacist-managed anticoagulation clinic: Improving patient care. Open Med (2009) 1.12

Potassium channel diversity in the pulmonary arteries and pulmonary veins: implications for regulation of the pulmonary vasculature in health and during pulmonary hypertension. Pharmacol Ther (2007) 1.11

Hypoxic pulmonary vasoconstriction: redox regulation of O2-sensitive K+ channels by a mitochondrial O2-sensor in resistance artery smooth muscle cells. J Mol Cell Cardiol (2004) 1.11

Role for DNA damage signaling in pulmonary arterial hypertension. Circulation (2013) 1.11

In vitro and in vivo antifungal activities of T-2307, a novel arylamidine. Antimicrob Agents Chemother (2008) 1.10

Oxygen-sensitive Kv channel gene transfer confers oxygen responsiveness to preterm rabbit and remodeled human ductus arteriosus: implications for infants with patent ductus arteriosus. Circulation (2004) 1.09